Clinical Trial Update: KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for KD025 in diffuse cutaneous systemic sclerosis is terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis

Drugs mentioned

• KD025

Snippet

Sponsor: Kadmon, a Sanofi Company | Conditions: System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2023-08-30